KRSA-028 / Korsana Biosciences - LARVOL DELTA

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut. (FierceBiotech) - "Korsana’s lead Alzheimer’s candidate, KRSA-028, was discovered in partnership with Paragon Therapeutics, a protein-engineering specialist...Korsana plans to bring KRSA-028 into the clinic in early 2027, with initial safety data reading out in the middle of the year and proof-of-concept evidence that the antibody can eliminate amyloid plaques by the end of the year, Violin told Fierce Biotech in an interview."

Clinical data • Licensing / partnership • New trial • Alzheimer's Disease

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. (FierceBiotech) - "The biotech has earmarked $2 million of the proceeds to take EIR-1003, its lead drug for eye conditions like glaucoma, diabetic retinopathy and uveal melanoma, through preclinical development. Another $5 million will be set aside to bankroll phase 1/1b clinical trials, which are penciled in for 2027, EIR explained in the filing."

Financing • New P1 trial • Diabetic Retinopathy • Glaucoma • Uveal Melanoma